Gilead Sciences, Inc. (GILD) stock analysis

Gilead Sciences, Inc. — Healthcare · Drug Manufacturers—General carries a Plainview business-quality score of 6.5/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.

On the fundamentals, Gilead Sciences, Inc. shows trailing revenue of $30.46B, a 79.6% gross margin, net debt of $20.65B, a loss per share of -2.79, valued at about 5.9x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.

• Current Price: $143.72
• YTD Return: +18.2%
• Revenue TTM: $30.46B
• Revenue Trend: YoY +10.2%
• Gross Margin: 79.6%
• Net Cash: $-20.65B
• EPS: -2.79
• P/S Ratio: 5.9x

Compare: GILD vs UNH · GILD vs JNJ · GILD vs LLY | Also: UNH, JNJ, LLY, PFE, MRK, ABBV